title: Cardiovascular effects of inhaled nitric oxide in a canine model of cardiomyopathy.
abstract: BACKGROUND
  The inhalation of nitric oxide (NO) in patients with heart failure decreases pulmonary vascular resistance (PVR) and is associated with an increase in pulmonary artery wedge pressure (PAWP). The mechanism for this effect remains unclear.
  
  
  METHODS
  In dogs rapid-paced for 8 weeks to induce cardiac dysfunction, we performed left ventricular pressure-volume analysis of unpaced hearts in situ to determine whether during NO inhalation (80 ppm), the mechanism for the rise in PAWP is due to: 1) primary pulmonary vasodilation; 2) a direct negative inotropic effect; or 3) impairment of ventricular relaxation.
  
  
  RESULTS
  Inhalation of NO decreased PVR by 51%+/-3.8% (257+/-25 vs 127+/-18 dynes x sec x cm(-5) [NO 80 ppm]; p < 0.001) and increased PAWP (15.4+/-2.4 vs 18.1+/-2.6 mm Hg [NO 80 ppm]; p < 0.001). Calculated systemic vascular resistance remained unchanged. Left ventricular (LV) end-diastolic pressure rose (16.4+/-1.9 vs 19.1+/-1.8 mm Hg [NO 80 ppm]; p < 0.001), as did LV end-diastolic volume (83.5+/-4.0 vs 77.0+/-3.4 mL [NO 80 ppm]; p = 0.006). LV peak +dP/dt was unchanged by NO (1,082+/-105 vs 1,142+/-111 mm Hg/sec [NO 80 ppm]; p = NS). There was a trend toward a stroke volume increase (17.4+/-1.2 vs 18.8+/-1.3 mL; p = NS), but the relaxation time constant and end-diastolic pressure-volume relation were both unchanged.
  
  
  CONCLUSIONS
  In this canine model of cardiomyopathy, inhaled NO decreases pulmonary vascular resistance. The associated increase in left ventricular filling pressure appears to be secondary to a primary pulmonary vasodilator effect of NO without primary effects on the contractile or relaxation properties of the left ventricle.
authors.affiliation: Department of Medicine, University of Pennsylvania Health System, Philadelphia, USA. lohe@mail.med.upenn.edu
authors.forename: E
authors.initials: E
authors.lastname: Loh
authors.forename: E B
authors.initials: EB
authors.lastname: Lankford
authors.forename: D J
authors.initials: DJ
authors.lastname: Polidori
authors.forename: E B
authors.initials: EB
authors.lastname: Doering-Lubit
authors.forename: C W
authors.initials: CW
authors.lastname: Hanson
authors.forename: M A
authors.initials: MA
authors.lastname: Acker
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D009202:Cardiomyopathies / Q000503:physiopathology*; D002319:Cardiovascular System / Q000187:drug effects*; D004195:Disease Models, Animal; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D009569:Nitric Oxide / Q000008:administration & dosage / Q000494:pharmacology*; D011669:Pulmonary Wedge Pressure; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects*; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D014665:Vasodilator Agents; D009569:Nitric Oxide